But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...